Medicines & supplements – Current GIS Alerts 2026
Found 774 alerts in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
XALOPTIC FREE
It was found that the specification limit for related substances was exceeded in batches of the medicinal product Xaloptic Free, with a likelihood of this non‑compliance occurring in further batches. Potential effects: possible lack of efficacy or unforeseen adverse reactions.
IRCOLON FORTE
Only a labelling error of the expiry date was found (02.2021 instead of 02.2020), with no indication of quality or safety hazards for the product. After confirmation of shelf-life extension to 3 years, the risk was considered negligible. Potential effects: none or minimal risk, possibly uncertainty about the actual expiry date.
ROTARIX
Irregularities in the manufacturing process were detected, leading to possible insufficient filling of the last 50 oral applicators of the Rotarix batch, meaning failure to meet quality requirements for the volume parameter. Potential effects: lack of vaccination efficacy.
BENZACNE
A quality defect of the product was found regarding the gel appearance and active substance content, resulting from a defect of the immediate packaging, which may lead to improper quality and performance of the product. Potential effects: lack of treatment efficacy or unpredictable drug action.
BENODIL
Out-of-specification results were found in archival samples tested by the manufacturer, regarding the parameter of budesonide-related substances content, which means failure to meet established quality requirements. Potential effects: possible lack of treatment efficacy or unforeseen adverse reactions.
BENODIL
A quality defect was identified consisting of out-of-specification results for the parameter of budesonide-related substances content, which may indicate an improper impurity profile and lack of compliance with quality requirements. Potential effects: possible reduced treatment efficacy or increased risk of adverse reactions.
PRESARTAN
Impurities of N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) were detected in the active substance Losartanum kalicum from the manufacturer Zhejiang Huahai Pharmaceutical Co. Ltd. Potential effects: possible carcinogenic effects and health risks with long-term use.
PRESARTAN H
The risk may be caused by the presence of nitrosamine-group contaminants in the active substance contained in these medicinal products, which may affect human health and life. Potential effects: possible carcinogenic effects, chronic health risk, potential complications with long-term use.
PRESARTAN H
Detected nitrosamine-group impurities (NDMA and NDEA) in the active substance losartan potassium, which may affect human health and life, even though the levels do not exceed acceptable limits. Potential effects: possible carcinogenic effects and health complications with long-term use.
PRESARTAN
This risk may be caused by the presence of nitrosamine-group impurities in the active substance contained in the above-mentioned medicinal products, which may affect human health and life. Potential effects: possible carcinogenic effects and health complications during long-term use.
KORZEŃ ARCYDZIĘGLA
Failure to meet quality requirements of the medicinal product was found due to the presence of disqualifying features, which makes a potential risk to patients’ health or life plausible. Potential effects: lack of efficacy, possible adverse effects or health complications.
GLICEROL
Out-of-specification results were found for aldehydes, sugars, impurity A and related substances during stability testing of batch 01916, which makes a potential threat to the quality and safety of the medicinal product plausible. Potential effects: lack of efficacy or unforeseen adverse reactions.
EURESPAL
Unfavorable benefit-risk balance of the active substance fenspiride shown in non-clinical studies. Potential effects: threat to patients' health or life.
PULNEO O SMAKU COLI
An unfavourable benefit-risk ratio for the active substance fenspiride, potentially posing a risk to patients’ health or life, with the probability of harm to a person considered significant. Potential effects: serious adverse reactions, complications, threat to health or life.
EUREFIN
Unfavourable benefit–risk ratio for the active substance fenspiride identified from non-clinical studies; an EU review procedure initiated. Potential effects: serious adverse reactions, threat to health or life.
PULNEO O SMAKU COLI
An unfavourable benefit-risk balance was identified for the active substance fenspiride, which may represent a real and highly probable risk to patients’ health or life. Potential effects: serious adverse reactions, risk to health or life.
EURESPAL
Unfavourable benefit-risk ratio for the active substance fenspiride; the French agency ANSM initiated an urgent EU re-evaluation procedure. Potential effects: deterioration of health, risk of complications.
EURESPAL
Unfavourable benefit–risk balance for the active substance fenspiride; potential public health risk. The French agency (ANSM) initiated an urgent EU review. Potential effects: risk to health or life.
FENSPOGAL
Unfavourable benefit-risk ratio for the active substance fenspiride, causing a potential, real and highly probable risk to patients' health or life, justifying immediate suspension and prohibition of placing the product on the market. Potential effects: serious adverse reactions, complications, life‑threatening events.
EURESPAL
Unfavourable benefit–risk balance of the active substance fenspiride indicated by non-clinical studies. Potential effects: serious adverse reactions, threat to health or life.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.